A

Allogene Therapeutics, Inc. (ALLO)

NMS – Real vaqt narxi. Valyuta: USD

2.30

+0.02 (0.88%)

Yopilishda: May 12, 2026, 4:00 PM EDT

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

A

Allogene Therapeutics, Inc. (ALLO)

NMS – Real vaqt narxi. Valyuta: USD

2.30

+0.02 (0.88%)

Yopilishda: May 12, 2026, 4:00 PM EDT

06.05.2026

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

Conference Call and Webcast Scheduled for May 13, 2026 at 2 p.m. PT/5 p.m. ET SOUTH SAN FRANCISCO, Calif.

21.04.2026

Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia

SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that regulatory authorities in South Korea and Australia have cleared the Company to expand its pivotal Phase 2 ALPHA3 study evaluating cemacabtagene ansegedleucel (cema-cel) in first-line (1L) consolidation treatment for patients with large B-cell lymphoma (LBCL).

20.04.2026

Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026

SOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products, today announced upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting, April 17-22, 2026, in San Diego, Calif.

16.04.2026

Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced the closing of its previously announced underwritten public offering of 87,500,000 shares of its common stock at a price to the public of $2.00 per share. In addition, the underwriters partially exercised their option and purchased 12,700,000 additional shares of common stock. Including the option exercise, the aggregate gross proceeds from this offering were $200.4 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Allogene.

15.04.2026

Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases

SOUTH SAN FRANCISCO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced the publication of pre-clinical data for ALLO-329 in Nature Communications. ALLO-329 is an investigational allogeneic CAR T product developed specifically for autoimmune diseases.

15.04.2026

Allogene Therapeutics Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced the pricing of an underwritten public offering of 87,500,000 shares of its common stock at a price to the public of $2.00 per share. The gross proceeds from this offering are expected to be $175 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Allogene. The offering is expected to close on or about April 16, 2026, subject to customary closing conditions. In addition, Allogene has granted the underwriters for the offering a 30-day option to purchase up to 13,125,000 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.

14.04.2026

ALLO Rises on Strong MRD Clearance With Cema-Cel in ALPHA3 Study

Allogene jumps as cema-cel shows strong MRD clearance and safety in the ALPHA3 study, signaling potential in first-line LBCL treatment.

Videolar

No Data

There is no data to display

Press-relizlar

21.04.2026

Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia

SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that regulatory authorities in South Korea and Australia have cleared the Company to expand its pivotal Phase 2 ALPHA3 study evaluating cemacabtagene ansegedleucel (cema-cel) in first-line (1L) consolidation treatment for patients with large B-cell lymphoma (LBCL).

20.04.2026

Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026

SOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products, today announced upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting, April 17-22, 2026, in San Diego, Calif.

16.04.2026

Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced the closing of its previously announced underwritten public offering of 87,500,000 shares of its common stock at a price to the public of $2.00 per share. In addition, the underwriters partially exercised their option and purchased 12,700,000 additional shares of common stock. Including the option exercise, the aggregate gross proceeds from this offering were $200.4 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Allogene.

15.04.2026

Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases

SOUTH SAN FRANCISCO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced the publication of pre-clinical data for ALLO-329 in Nature Communications. ALLO-329 is an investigational allogeneic CAR T product developed specifically for autoimmune diseases.

Search stocks

Allogene Therapeutics, Inc. (ALLO)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Allogene Therapeutics, Inc. (ALLO)

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia

Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026

Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock

Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases

Allogene Therapeutics Announces Pricing of Public Offering of Common Stock

ALLO Rises on Strong MRD Clearance With Cema-Cel in ALPHA3 Study

Videolar

No Data

Press-relizlar

Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia

Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026

Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock

Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases